CA
NZ
UK
AU
IND
US
…
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia and New Zealand. It offers topical anti-inflammatory creams, sprays, and roll-ons for the relief of joint and muscle pain under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. The company is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities, as well as sales and distribution activities. It exports its products to the United Kingdom and the United Arab Emirates. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Wellnex Life Ltd is an Australian-listed company (WNX.AX) for which publicly available detail about core operations is limited. Because disclosures are scarce, growth drivers and competitive position are unclear; if the business operates in consumer health, potential attractions may include exposure to ageing populations and rising health spending, but these links are unverified.
Principal risks include limited public disclosure, execution and financing constraints typical of small listed companies, and regulatory or product-safety exposure if the company is active in health-related products.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -4.55M | -15.60M | -13.74M | -13.85M | -7.45M |
| Net income | -4.55M | -15.60M | -13.74M | -13.85M | -7.45M |
| Selling general administrative | - | 2.56M | 7.86M | 7.14M | 8.58M |
| Selling and marketing expenses | - | 2.74M | 2.89M | 4.43M | 1.67M |
| Gross profit | 2.78M | 6.88M | -0.78M | 4.74M | 4.50M |
| Reconciled depreciation | - | - | 0.77M | 0.27M | 0.12M |
| Ebit | -2.43M | -8.00M | -11.34M | -7.10M | -5.68M |
| Ebitda | -0.81M | -6.62M | -10.57M | -6.82M | -5.56M |
| Depreciation and amortization | 1.62M | 1.38M | 0.77M | 0.27M | 0.12M |
| Operating income | -2.43M | -6.62M | -7.51M | -7.10M | -5.68M |
| Other operating expenses | 27.27M | 30.25M | 24.44M | 34.99M | 24.48M |
| Interest expense | 1.54M | 2.63M | 2.40M | 1.68M | 0.96M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 2.69M | 1.73M | 1.68M | 0.96M |
| Net interest income | - | - | -2.40M | -1.68M | -0.96M |
| Income tax expense | - | - | -0.77M | 1.70M | 1.14M |
| Total revenue | 24.84M | 23.62M | 16.93M | 27.88M | 18.61M |
| Total operating expenses | 5.22M | 13.50M | 6.73M | 11.85M | 10.37M |
| Cost of revenue | 22.05M | 16.75M | 17.71M | 23.14M | 14.11M |
| Total other income expense net | -2.12M | -8.98M | -6.23M | -5.05M | -0.62M |
| Net income from continuing ops | - | - | -13.74M | -13.85M | -7.45M |
| Net income applicable to common shares | - | -15.60M | -13.74M | -13.85M | -7.45M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 23.78M | 27.84M | 31.48M | 15.04M | 19.61M |
| Intangible assets | 0.04M | 19.72M | - | 2.47M | 0.46M |
| Other current assets | 20.04M | 1.54M | 0.98M | 2.47M | 0.17M |
| Total liab | 16.33M | 16.59M | 24.30M | 14.45M | 15.25M |
| Total stockholder equity | 7.45M | 11.25M | 7.18M | 0.59M | 4.36M |
| Deferred long term liab | - | - | - | 0.52M | - |
| Other current liab | 1.11M | 0.83M | 0.46M | 1.04M | 1.63M |
| Common stock | 152.11M | 151.45M | 131.08M | 112.42M | 102.62M |
| Capital stock | - | - | - | 112.42M | 102.62M |
| Retained earnings | -144.66M | -140.97M | -127.45M | -115.56M | -101.71M |
| Other liab | - | - | - | 0.10M | 0.06M |
| Good will | - | - | - | 0.99M | 5.00M |
| Other assets | - | - | - | 0.52M | - |
| Cash | 0.86M | 0.50M | 0.90M | 0.32M | 3.18M |
| Cash and equivalents | - | - | - | 0.32M | 3.18M |
| Total current liabilities | 16.27M | 16.48M | 24.21M | 14.30M | 9.80M |
| Current deferred revenue | 0.21M | - | 5.65M | - | - |
| Net debt | 8.82M | 4.95M | 9.76M | 6.63M | 4.68M |
| Short term debt | 9.68M | 5.45M | 10.67M | 6.90M | 2.47M |
| Short long term debt | - | - | - | 6.79M | 2.38M |
| Short long term debt total | 9.68M | 5.45M | 10.67M | 6.95M | 7.86M |
| Other stockholder equity | - | - | - | 3.73M | 3.45M |
| Property plant equipment | - | - | - | 0.20M | 0.31M |
| Total current assets | 23.75M | 8.11M | 10.45M | 11.38M | 13.84M |
| Net tangible assets | - | - | - | -2.35M | -1.10M |
| Net receivables | 2.48M | 2.59M | 4.38M | 4.60M | 6.17M |
| Long term debt | - | - | - | 0.00M | 5.20M |
| Inventory | 0.37M | 3.48M | 4.19M | 3.03M | 4.32M |
| Accounts payable | 5.27M | 10.20M | 7.44M | 6.35M | 5.71M |
| Accumulated other comprehensive income | 0.00M | 0.78M | 3.55M | 3.73M | 3.45M |
| Non currrent assets other | - | - | 20.95M | - | - |
| Non current assets total | 0.04M | 19.73M | 21.03M | 3.66M | 5.77M |
| Capital lease obligations | - | - | - | 0.16M | 0.28M |
| Long term debt total | - | - | - | 0.05M | 5.39M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | -13.42M | -2.20M | -0.00M |
| Change to liabilities | - | - | - | 0.00M | 5.82M |
| Total cashflows from investing activities | 0.01M | -8.29M | -13.42M | -2.20M | -3.65M |
| Net borrowings | - | - | 3.58M | -1.93M | 6.23M |
| Total cash from financing activities | 3.17M | 8.55M | 20.82M | 5.53M | 7.66M |
| Change to operating activities | - | - | - | - | 0.53M |
| Net income | -4.55M | -15.60M | -13.74M | -13.85M | -7.45M |
| Change in cash | 0.36M | -0.41M | 0.58M | -2.86M | -4.59M |
| Begin period cash flow | 0.50M | 0.90M | 0.32M | 3.18M | 7.78M |
| End period cash flow | 0.86M | 0.50M | 0.90M | 0.32M | 3.18M |
| Total cash from operating activities | -2.81M | -0.67M | -6.82M | -6.19M | -8.61M |
| Issuance of capital stock | - | - | 20.15M | 8.17M | 2.18M |
| Depreciation | 1.62M | 1.38M | 0.82M | 0.27M | 0.15M |
| Other cashflows from investing activities | 0.01M | -8.29M | -0.12M | -2.20M | 0.67M |
| Dividends paid | - | - | - | 10.45M | 9.70M |
| Change to inventory | 3.36M | - | -1.57M | 1.29M | -3.65M |
| Change to account receivables | -2.67M | - | -0.25M | 1.57M | -5.29M |
| Sale purchase of stock | - | 15.90M | -2.80M | -0.71M | -0.17M |
| Other cashflows from financing activities | -1.14M | 8.55M | -0.11M | 20.77M | 18.73M |
| Change to netincome | - | - | - | 7.38M | 1.28M |
| Capital expenditures | 0.00M | 0.00M | 6.82M | 0.00M | 0.04M |
| Change in working capital | -1.44M | 0.00M | 1.37M | 2.06M | -2.59M |
| Stock based compensation | - | 4.19M | 0.49M | 0.28M | 0.63M |
| Other non cash items | 1.57M | 9.37M | 4.24M | 2.84M | 4.69M |
| Free cash flow | -2.81M | -0.67M | -6.82M | -6.19M | -8.65M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| WNX Wellnex Life Ltd |
- -% |
0.06 | - | 43.48 | 0.19 | 0.65 | 0.55 | -4.76 |
| A2M The a2 Milk Company Ltd |
-0.13 1.79% |
7.13 | 29.04 | 28.74 | 2.68 | 5.94 | 2.85 | 17.82 |
| BGA Bega Cheese Ltd |
0.02 0.31% |
6.43 | 35.61 | 22.94 | 0.52 | 1.93 | 0.60 | 11.82 |
| CBO Cobram Estate Olives Ltd |
- -% |
2.70 | - | - | 4.79 | 2.48 | 6.63 | 185.44 |
| RIC Ridley Corporation Ltd |
- -% |
2.68 | 38.29 | 13.42 | 0.35 | 2.01 | 0.53 | 4.50 |
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia and New Zealand. It offers topical anti-inflammatory creams, sprays, and roll-ons for the relief of joint and muscle pain under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. The company is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities, as well as sales and distribution activities. It exports its products to the United Kingdom and the United Arab Emirates. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Port Park - Building 2, Port Melbourne, VIC, Australia, 3207
61 3 8399 9419
| Name | Title | Year Born |
|---|---|---|
| Mr. George Karafotias B.Com. | CEO, CFO & Exec. Director | NA |
| Mr. Zlatko Bozinovski | Chief Strategy Officer & Exec. Director | NA |
| Mr. Zheng Li | Company Sec. & Independent Non-Exec. Director | NA |
| Ms. Angela Coppola | Fin. & Admin. Exec. | NA |
| Mr. George Karafotias B.Com. | CEO, CFO & Executive Director | NA |
| Mr. Zlatko Bozinovski | Chief Strategy Officer & Executive Director | NA |
| Mr. Zheng Li | Company Secretary | NA |
| Ms. Angela Coppola | Finance & Administration Executive | NA |
| Mr. George Karafotias B.Com. | CEO, CFO & Executive Director | NA |
| Mr. Zlatko Bozinovski | Chief Strategy Officer & Executive Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...